Get the Stockscreener App
22.05
2.36%
0.61
Caredx Inc stock is traded at $22.05, with a volume of 214.00K.
It is up +2.36% in the last 24 hours and up +22.46% over the past month.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
See More
Previous Close:
$21.44
Open:
$21.4
24h Volume:
214.00K
Relative Volume:
0.31
Market Cap:
$1.14B
Revenue:
$412.82M
Net Income/Loss:
$-8.19M
P/E Ratio:
-143.09
EPS:
-0.1541
Net Cash Flow:
$64.17M
1W Performance:
+2.07%
1M Performance:
+22.46%
6M Performance:
+40.49%
1Y Performance:
+42.59%
1-Day Range:
$21.01
$22.20
1-Week Range:
$20.39
$22.20
52-Week Range:
$10.96
$23.24
Caredx Inc Stock (CDNA) Company Profile
Name
Caredx Inc
Sector
Industry
Phone
415-287-2300
Address
8000 MARINA BLVD, BRISBANE, CA
Compare CDNA vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDNA
Caredx Inc
|
22.09 | 1.11B | 412.82M | -8.19M | 64.17M | -0.1541 |
TMO
Thermo Fisher Scientific Inc
|
463.52 | 176.32B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.90 | 124.33B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
561.59 | 45.14B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
348.66 | 34.41B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.81 | 33.53B | 7.07B | 1.29B | 993.00M | 4.5355 |
Caredx Inc Stock (CDNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-26-25 | Initiated | William Blair | Mkt Perform |
| Jan-15-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-28-24 | Initiated | Wells Fargo | Underweight |
| Aug-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| May-13-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-24 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-09-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| Aug-15-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-11-23 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-07-23 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-03-23 | Downgrade | Craig Hallum | Buy → Hold |
| Mar-03-23 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Jul-20-21 | Resumed | BTIG Research | Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-26-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-30-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-08-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-02-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-26-20 | Initiated | BTIG Research | Buy |
| Jun-19-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| May-09-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-15-19 | Initiated | Jefferies | Buy |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Neutral |
| Nov-27-17 | Initiated | H.C. Wainwright | Buy |
| Jun-14-16 | Reiterated | Mizuho | Buy |
| Sep-29-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-25-15 | Initiated | Craig Hallum | Buy |
| Mar-18-15 | Reiterated | Mizuho | Buy |
View All
Caredx Inc Stock (CDNA) Latest News
Technical Reactions to CDNA Trends in Macro Strategies - Stock Traders Daily
Insider Sell: Jeffrey Novack Sells 2,688 Shares of CareDx Inc (C - GuruFocus
CareDx (NASDAQ: CDNA) counsel's 2,688-share sale under 10b5-1 - Stock Titan
CareDx (CDNA) Q1 2026 Earnings Call Transcript - AOL.com
[144] CareDx, Inc. SEC Filing - Stock Titan
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The National Law Review
A Look At CareDx (CDNA) Valuation After Recent Share Price Momentum Cools - Yahoo Finance
CareDx (CDNA) General Counsel has 2,873 shares withheld to cover RSU taxes - Stock Titan
How Investors Are Reacting To CareDx (CDNA) Profitability Milestone And Higher 2026 Revenue Guidance - Sahm
CareDx (NASDAQ:CDNA) Upgraded to Strong-Buy at Wall Street Zen - MarketBeat
MSN Money - MSN
23 new CareDx hires receive 63,856 stock units under Nasdaq rule - Stock Titan
CareDx sharpens focus on core testing services - MSN
CareDx (CDNA) Q2 2025 Earnings Transcript - AOL.com
CareDx : 2025 Annual Report - marketscreener.com
CareDx : 2026 Proxy Statement - marketscreener.com
CDNA SEC FilingsCaredx 10-K, 10-Q, 8-K Forms - Stock Titan
Analysts Conflicted on These Healthcare Names: CareDx (CDNA), Biogen (BIIB) and Guardant Health (GH) - The Globe and Mail
H.C. Wainwright reiterates Neutral rating on CareDx stock By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Neutral rating on CareDx stock - Investing.com
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), Stryker (SYK) and CareDx (CDNA) - The Globe and Mail
CareDx Acquires Navaris and Divests Lab Products to Accelerate Growth - HarianBasis.co
Analysts Offer Insights on Healthcare Companies: CareDx (CDNA) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
CareDx Earnings Call: Growth Accelerates Amid Bold Pivot - TipRanks
CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing - The National Law Review
Q1 2026 Presentation (04/28/2026 00: 00 - marketscreener.com
CareDx (NASDAQ:CDNA) Trading Down 8.7%What's Next? - MarketBeat
CareDx sharpens precision medicine focus with $260m Naveris acquisition - Yahoo Finance
Caredx to acquire Naveris for up to $260 million - BioWorld News
CareDx : ESG Report (CareDx 2026 ESG Report) - marketscreener.com
CDNA Maintained by BTIG -- Price Target Raised to $28.00 - GuruFocus
CareDx to Acquire Oncology Diagnostics Company Naveris for $160 Million - Clinical Lab Products
CareDx, Inc Q1 2026 Earnings Call Summary - Yahoo Finance
CareDx (NASDAQ:CDNA) Price Target Raised to $28.00 at BTIG Research - MarketBeat
CareDx, Inc (NASDAQ:CDNA) Q1 2026 Earnings Call Transcript - Insider Monkey
BTIG raises CareDx stock price target on oncology diagnostics deal - Investing.com UK
BTIG raises CareDx stock price target on oncology diagnostics deal By Investing.com - Investing.com Nigeria
CareDx Inc (CDNA) Q1 2026 Earnings Call Highlights: Strong Reven - GuruFocus
CareDx Announces First Quarter 2026 Financial Results - BioSpace
CareDx Q1 2026 Earnings Call Transcript - MarketBeat
CareDx to acquire Naveris for $160M up-front, $100M in revenue milestones - TipRanks
CareDx to acquire oncology diagnostics firm Naveris for $160M By Investing.com - Investing.com South Africa
CareDx (CDNA) Q1 2026: EPS $0.05 Beats -$0.03 Est; Revenue $118M - GuruFocus
CareDx to Acquire Naveris to Expand Into Cancer MRD Testing - Yahoo Finance
CDNA Adjusts 2026 EBITDA Forecast to $43M-$57M Range - GuruFocus
CDNA Expands Precision Medicine Services with Naveris Acquisitio - GuruFocus
Earnings call transcript: CareDx Q1 2026 earnings beat expectations By Investing.com - Investing.com India
CareDx, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:CDNA) 2026-04-28 - Seeking Alpha
CareDx Q1 Earnings Call Highlights - MarketBeat
CDNA Reports Strong Q1 Revenue Growth and Strategic Developments - GuruFocus
Caredx Inc Stock (CDNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.58%
10.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):